Minimally invasive local delivery of cardiac gene therapy
Active Project Grant Awarded Last action
- Award ID
- R42HL149495
- Recipient
-
Corami Biotech, Inc. UEI V4UYGDK9NEB3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,293,419
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 89% complete
- Place of performance
- Memphis, TN 38120, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cardiovascular diseases (CVD) are the leading cause of death in the united states, and current therapies are hindered by inefficient delivery methods, high systemic off-target exposure, and prohibitive costs, particularly for gene therapies. Corami biotech's platform combines a minimally invasive epicardial delivery device (epicor™) and a tunable hydrogel (gelcor™) which together localize therapeutic to the heart leading to significantly lower effective dose of gene therapy compared to systemic delivery while minimizing off-target expression.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,293,419 |
Quick answers
Who received award R42HL149495?
R42HL149495 was awarded to Corami Biotech, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 23, 2019.
How much is award R42HL149495 worth?
$1,293,419 has been obligated on R42HL149495.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award